Clinical Trial Update: Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating peginterferon alfa-2b for chronic hepatitis C in Chinese patients has completed, examining efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2b (Peginterferon alfa-2b)

Snippet

Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED